Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $66.75

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $66.75.

A number of research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors have recently modified their holdings of ARCT. Franklin Resources Inc. grew its holdings in Arcturus Therapeutics by 54.6% in the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after purchasing an additional 36,714 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after acquiring an additional 712,650 shares during the period. Empire Life Investments Inc. purchased a new stake in Arcturus Therapeutics in the 3rd quarter worth $3,498,000. XTX Topco Ltd purchased a new position in Arcturus Therapeutics during the second quarter valued at $596,000. Finally, Squarepoint Ops LLC purchased a new position in Arcturus Therapeutics during the second quarter valued at $718,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Down 2.3 %

NASDAQ:ARCT opened at $16.41 on Friday. The stock has a market capitalization of $444.55 million, a price-to-earnings ratio of -7.39 and a beta of 2.63. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00. The firm has a 50 day moving average of $17.38 and a 200 day moving average of $19.80.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same period last year, the business posted ($0.61) earnings per share. As a group, analysts expect that Arcturus Therapeutics will post -2.31 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.